<?xml version="1.0" encoding="UTF-8"?>
<document id="27833130">
	<sentence id="s1" text="Silencing of PTPN3 restored sensitivity to cisplatin and doxorubicin in resistant ovarian cancer cells.">
		<entity id="s1.e1" charOffset="13-18"
			type="GENE" text="PTPN3" ontology_id="5774"/>
		<entity id="s1.e2" charOffset="90-96"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="true"/>
	</sentence>
	<sentence id="s2" text="Down-regulation of PTPN3 also inhibited cell cycle progression, migration, stemness in vitro and the tumorigenicity of resistant ovarian cancer cells in vivo.">
		<entity id="s2.e1" charOffset="19-24"
			type="GENE" text="PTPN3" ontology_id="5774"/>
		<entity id="s2.e2" charOffset="137-143"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e2" pgr="true"/>
	</sentence>
	<sentence id="s3" text="Meanwhile, the expression of PTPN3 was found to be regulated by miR-199 in resistant ovarian cancer cells.">
		<entity id="s3.e1" charOffset="29-34"
			type="GENE" text="PTPN3" ontology_id="5774"/>
		<entity id="s3.e2" charOffset="93-99"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e2" pgr="true"/>
	</sentence>
	<sentence id="s4" text="These findings suggest that PTPN3 promotes tumorigenicity, stemness and drug resistance in ovarian cancer, and thus is a potential therapeutic target for the treatment of ovarian cancer">
		<entity id="s4.e1" charOffset="28-33"
			type="GENE" text="PTPN3" ontology_id="5774"/>
		<entity id="s4.e2" charOffset="99-105"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="true"/>
	</sentence>
</document>
